Deutsche Bank
ARGS

Deutsche Bank’s Argos Therapeutics, Inc. ARGS Stock Holding History

Deutsche Bank’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1
Closed – – 5815
2018
Q1 		$0 Sell
1
-1
-50% -$2 ﹤0.01% 5858
2017
Q4 		$0 Hold
2
– – ﹤0.01% 5379
2017
Q3 		$0 Sell
2
-35
-95% -$168 ﹤0.01% 5365
2017
Q2 		$0 Sell
37
-5,957
-99% -$50.7K ﹤0.01% 5404
2017
Q1 		$53K Buy
5,994
+5,531
+1,195% +$350K ﹤0.01% 4201
2016
Q4 		$44K Buy
463
+278
+150% +$26K ﹤0.01% 4390
2016
Q3 		$17K Sell
185
-245
-57% -$25.6K ﹤0.01% 4579
2016
Q2 		$51K Buy
+430
New +$57.4K ﹤0.01% 4407
2016
Q1 		– Sell
-12
Closed – – 5624
2015
Q4 		$0 Buy
+12
New +$1.01K ﹤0.01% 5647
2015
Q1 		– Sell
-991
Closed -$198K – 6561
2014
Q4 		$198K Buy
991
+282
+40% +$50.7K ﹤0.01% 4308
2014
Q3 		$142K Sell
709
-776
-52% -$121K ﹤0.01% 4289
2014
Q2 		$238K Buy
1,485
+21
+1% +$3.47K ﹤0.01% 4021
2014
Q1 		$291K Buy
+1,464
New +$293K ﹤0.01% 3684

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Deutsche Bank's ARGS Position: Q2 2018 in Review

Deutsche Bank sold out of Argos Therapeutics, Inc. (ARGS) in Q2 2018, closing a stake of 1 share.

Deutsche Bank first reported a position in ARGS in Q1 2014 and held it in 13 quarters. The position peaked at $291K in Q1 2014. 4 funds tracked by Wall St. Rank hold ARGS as of Q2 2018.

  • Deutsche Bank reported no remaining Argos Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
  • Deutsche Bank sold 1 Argos Therapeutics, Inc. share in Q2 2018.
  • Deutsche Bank first reported a position in Argos Therapeutics, Inc. in Q1 2014 and held it in 13 quarters.
  • Deutsche Bank's Argos Therapeutics, Inc. position peaked at $291K in Q1 2014.
  • 4 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q2 2018.

Based on Deutsche Bank's 13F filing for Q2 2018, filed 14 Aug 2018.